Mitsubishi Tanabe Pharma Corporation

Kunio Saruta

Norimitsu Hayashi

Osamu Sakurai

Hiroaki Sawamoto

Kenji Morokuma

Ritsuo Imashiro

Hiroaki Shitama

Hidekazu Tsujishima

Takashi Goi

Eri Ooboki

Maiko Hamada

Seigo Ishibuchi

Tetsuji Matsudaira

Naoto Fujie

Akiko Tarao

Maki Seki

Takashi Honjo

Yukio Aoyama

Atsushi Kawata

Shingo Ogata

Nobuatsu Matoba

Eri Oboki

Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

Imide derivatives and use thereof as medicine

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CRor nitrogen atom; Ris hydrogen and the like; Ris alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Aromatic heterocyclic compound

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

Growing community of inventors

Osaka, Japan

Kunio Saruta